Abeona Therapeutics Inc ABEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABEO is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
-
Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter
-
Abeona Therapeutics Provides Regulatory Update on Pz-cel
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility
-
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
-
Thinking about buying stock in Ocean Biomedical, Rush Street Interactive, Vivani Medical, Abeona Therapeutics, or Honest Company?
Trading Information
- Previous Close Price
- $3.17
- Day Range
- $3.05–3.28
- 52-Week Range
- $2.83–9.01
- Bid/Ask
- $3.20 / $3.26
- Market Cap
- $87.26 Mil
- Volume/Avg
- 1.1 Mil / 512,199
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 84
Comparables
Valuation
Metric
|
ABEO
|
CBAY
|
VRDN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.71 | 12.65 | 2.91 |
Price/Sales | 19.49 | 111.01 | 1,810.15 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABEO
CBAY
VRDN
Financial Strength
Metric
|
ABEO
|
CBAY
|
VRDN
|
---|---|---|---|
Quick Ratio | 4.07 | 10.70 | 17.93 |
Current Ratio | 4.15 | 10.96 | 18.26 |
Interest Coverage | −133.70 | −5.27 | −137.76 |
Quick Ratio
ABEO
CBAY
VRDN
Profitability
Metric
|
ABEO
|
CBAY
|
VRDN
|
---|---|---|---|
Return on Assets (Normalized) | −64.39% | −30.06% | −42.76% |
Return on Equity (Normalized) | −211.48% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −163.63% | −30.87% | −50.70% |
Return on Assets
ABEO
CBAY
VRDN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfmszkbyq | Bqq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmygwlht | Wbtxft | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zscdwbjb | Vhspb | $97.8 Bil | |
MRNA
| Moderna Inc | Ghdljqbw | Mqyj | $38.8 Bil | |
ARGX
| argenx SE ADR | Hjwmtvjl | Dzk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vbhvgtjdy | Jzvc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ngmlhksc | Pbwytl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rzbggvfv | Zgscz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ldvktbyjb | Yssgcry | $12.5 Bil | |
INCY
| Incyte Corp | Pvzzctv | Fkvttdq | $11.5 Bil |